Amarin Corp. PLC (NASDAQ:AMRN) – Equities researchers at Cantor Fitzgerald issued their FY2016 earnings per share (EPS) estimates for shares of Amarin Corp. PLC in a note issued to investors on Monday. Cantor Fitzgerald analyst C. Russo expects that the firm will earn ($0.29) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $6.00 target price on the stock. Cantor Fitzgerald also issued estimates for Amarin Corp. PLC’s FY2017 earnings at ($0.14) EPS.

Amarin Corp. PLC (NASDAQ:AMRN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. The business earned $32.82 million during the quarter, compared to the consensus estimate of $29.97 million. During the same quarter in the prior year, the firm posted ($0.15) EPS. The company’s revenue for the quarter was up 85.4% on a year-over-year basis.

Other research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Amarin Corp. PLC in a report on Monday, August 8th. Zacks Investment Research raised Amarin Corp. PLC from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Thursday, August 4th. Finally, Jefferies Group reissued a “buy” rating and issued a $3.50 target price on shares of Amarin Corp. PLC in a report on Thursday, July 7th.

Shares of Amarin Corp. PLC (NASDAQ:AMRN) traded down 3.035% during midday trading on Wednesday, reaching $3.035. 1,218,064 shares of the company traded hands. The stock has a 50 day moving average price of $3.00 and a 200 day moving average price of $2.36. The firm’s market capitalization is $560.11 million. Amarin Corp. PLC has a 1-year low of $1.24 and a 1-year high of $3.46.

Hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. increased its stake in Amarin Corp. PLC by 9.3% in the second quarter. Ameriprise Financial Inc. now owns 1,187,983 shares of the biopharmaceutical company’s stock worth $2,567,000 after buying an additional 101,112 shares during the period. Acadian Asset Management LLC acquired a new stake in Amarin Corp. PLC during the second quarter worth $210,000. Timber Hill LLC increased its stake in Amarin Corp. PLC by 229.8% in the second quarter. Timber Hill LLC now owns 53,504 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 37,283 shares during the period. UBS Group AG increased its stake in Amarin Corp. PLC by 6.5% in the first quarter. UBS Group AG now owns 551,920 shares of the biopharmaceutical company’s stock worth $845,000 after buying an additional 33,662 shares during the period. Finally, State Street Corp increased its stake in Amarin Corp. PLC by 2.4% in the second quarter. State Street Corp now owns 104,259 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 2,491 shares during the period. Hedge funds and other institutional investors own 20.74% of the company’s stock.

About Amarin Corp. PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

5 Day Chart for NASDAQ:AMRN

Receive News & Stock Ratings for Amarin Corp. PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corp. PLC and related stocks with our FREE daily email newsletter.